Valuation: Abivax

Market Cap 7.93B 9.1B 7.49B 6.8B 12.74B 873B 12.8B 89.71B 34.62B 444B 34.17B 33.41B 1,428B P/E 2026 *
-25.7x
P/E 2027 * -30.2x
Enterprise Value 6.83B 7.84B 6.45B 5.86B 10.98B 752B 11.02B 77.29B 29.83B 382B 29.44B 28.78B 1,230B EV / Sales 2026 *
97.4x
EV / Sales 2027 * 87.7x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-2.88%
1 week-10.17%
Current month-6.71%
1 month-11.56%
3 months+5.57%
6 months-15.27%
Current year-24.42%
1 week 89
Extreme 89
101.7
1 month 89
Extreme 89
105.1
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 4.51
Extreme 4.51
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-2.88%-10.17%+30.19%+456.23% 9.1B
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -1.18%+2.37%+48.95%+162.63% 27.15B
Weighted average by Cap. -1.08%+1.47%+63.46%+142.49%

Financials

2026 *2027 *
Net sales 70.18M 80.48M 66.26M 60.17M 113M 7.72B 113M 794M 306M 3.93B 302M 296M 12.63B 79.52M 91.19M 75.09M 68.18M 128M 8.75B 128M 899M 347M 4.45B 343M 335M 14.31B
Net income -265M -304M -250M -227M -426M -29.18B -428M -3B -1.16B -14.83B -1.14B -1.12B -47.73B -231M -265M -218M -198M -371M -25.39B -372M -2.61B -1.01B -12.91B -994M -972M -41.54B
Net Debt -1.1B -1.26B -1.04B -942M -1.76B -121B -1.77B -12.42B -4.79B -61.43B -4.73B -4.63B -198B -956M -1.1B -903M -820M -1.54B -105B -1.54B -10.81B -4.17B -53.49B -4.12B -4.03B -172B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-18 €91.00 -2.88% 249,075
26-09-17 €93.70 +3.59% 124,050
26-09-16 €90.45 -3.62% 159,819
26-09-15 €93.85 -5.82% 126,106
26-09-14 €99.65 -1.63% 81,653
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
91.00EUR
Average target price
137.98EUR
Spread / Average Target
+51.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!